← Evidence map

ArticleCells2025

Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.

Uly Sumarni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Correction: Sumarni et al. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP. | OpenQuestion